Could SBRT Have Role in Metastatic Kidney Cancer?

Video

This video examines a pilot trial that tested stereotactic body radiotherapy plus nephrectomy in patients with renal cell carcinoma.

In this video, Thomas Schwaab, MD, PhD, of Roswell Park Cancer Institute in Buffalo, New York, discusses a pilot trial that tested stereotactic body radiotherapy (SBRT) plus nephrectomy in patients with renal cell carcinoma.

The research, which was published in Clinical Cancer Research, also provides evidence that immunotherapy may be an effective third element to this combination.

Video courtesy of Roswell Park Cancer Institute.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Blood-based markers of note in kidney cancer prognosis include circulating tumor DNA and proteomic markers, according to Michael B. Atkins, MD.
Clinical trials still have a role in improving outcomes with immunotherapy among those with kidney cancer.
Current research initiatives in the kidney cancer field include exploring anti–PD-1, anti–LAG-3, and anti–CTLA-4 combination regimens.